Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial

被引：2
|
作者：
Ahn, Myung-Ju
Camidge, D. Ross
Tiseo, Marcello
Reckamp, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Langer, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William
Kerstein, David
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Colorado Denver, Aurora, CO USA
[3] Univ Hosp Parma, Parma, Italy
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Odense Univ Hosp, Odense, Denmark
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[7] Univ Hosp Munich, Thorac Oncol Ctr Munich, Munich, Germany
[8] Swedish Canc Inst, Seattle, WA USA
[9] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[10] Otto Wagner Hosp, Vienna, Austria
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Yale Canc Ctr, New Haven, CT USA
[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
[14] Hosp Octubre, Dept Med Oncol, Madrid, Spain
[15] Vrije Univ VU Med Ctr, Amsterdam, Netherlands
[16] Levine Canc Inst, Charlotte, NC USA
[17] ARIAD Pharmaceut, Cambridge, MA USA
[18] Seoul Natl Univ Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Indirect Naive Comparison of ALK Inhibitors for ALK plus Non-Small Cell Lung Cancer (NSCLC) Post-Crizotinib Failure
    Reckamp, Karen L.
    Huang, Joice
    Huang, Hui
    Moore, Yan
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S313 - S314
  • [42] A phase II single-arm study of LDK378 in patients with ALK-activated (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
    Shaw, Alice Tsang
    Mok, Tony
    Spigel, David R.
    Nishio, Makoto
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Garcia-Campelo, M. Rosario
    Gruen, Harry J. M.
    Dakhil, Shaker R.
    Schaefer, Eric Scott
    Farrell, Nicholas John
    Blakesley, Rick E.
    Weir, Alexander
    Ristic, Mirta
    Selvaggi, Giovanni
    Scagliotti, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALKþ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
    Gettinger, Scott N.
    Huber, Rudolf M.
    Kim, Dong-Wan
    Bazhenova, Lyudmila
    Hansen, Karin Holmskov
    Tiseo, Marcello
    Langer, Corey J.
    Rodriguez, Luis G. Paz-Ares
    West, Howard L.
    Reckamp, Karen L.
    Weiss, Glen J.
    Smit, Egbert F.
    Hochmair, Maximilian J.
    Kim, Sang-We
    Ahn, Myung-Ju
    Kim, Edward S.
    Groen, Harry J. M.
    Pye, Joanna
    Liu, Yuyin
    Zhang, Pingkuan
    Vranceanu, Florin
    Camidge, Ross
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):
  • [44] Brigatinib versus crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: results from the phase 3 ALTA-1L trial
    Califano, R.
    Camidge, D.
    Kim, H. -R.
    Ahn, M. -J.
    Yang, J.
    Han, J. -Y.
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W.
    Griesinger, F.
    Felip, E.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    LUNG CANCER, 2020, 139 : S59 - S60
  • [45] Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK plus NSCLC).
    Berge, Eamon
    Delee, Maxon
    Lu, Xian
    Baron, Anna E.
    Solomon, Benjamin J.
    Doebele, Robert Charles
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.
    Ahn, Myung-Ju
    Kim, HyeRyun
    Yang, James Chih-Hsin
    Han, Ji-Youn
    Lee, Jong Seok
    Hochmair, Maximilian J.
    Li, Jacky Yu-Chung
    Chang, Gee-Chen
    Lee, Ki Hyeong
    Gridelli, Cesare
    Campelo, Rosario Garcia
    Delmonte, Angelo
    Kim, Dong-Wan
    Kerstein, David
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
    Huber, Rudolf M.
    Hansen, Karin H.
    Paz-Ares Rodriguez, Luis
    West, Howard L.
    Reckamp, Karen L.
    Leighl, Natasha B.
    Tiseo, Marcello
    Smit, Egbert F.
    Kim, Dong-Wan
    Gettinger, Scott N.
    Hochmair, Maximilian J.
    Kim, Sang-We
    Langer, Corey J.
    Ahn, Myung-Ju
    Kim, Edward S.
    Kerstein, David
    Groen, Harry J. M.
    Camidge, D. Ross
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : 404 - 415
  • [48] EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL
    Ferreira, Carlos G.
    Barrios, C.
    Shaw, Alice T.
    Shi, Yuankai
    De Pas, Tommaso M.
    Yang, Pan C.
    Riely, Greg J.
    Crino, Lucio
    Iyer, Shrividya
    Polli, Anna
    Lanzalone, Silvana
    Kim, Dong W.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S108
  • [49] The role of brigatinib in crizotinib-resistant non-small cell lung cancer
    Mezquita, Laura
    Planchard, David
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 123 - 130
  • [50] A Randomized, Phase 3 Study of Iruplinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK plus Non-small Cell Lung Cancer (NSCLC)
    Shi, Y.
    Chen, J.
    Yang, R.
    Wu, H.
    Wang, Z.
    Yang, W.
    Cui, J.
    Zhang, Y.
    Liu, C.
    Cheng, Y.
    Liu, Y.
    Shan, J.
    Wang, D.
    Yang, L.
    Hu, C.
    Zhao, J.
    Cao, R.
    Tan, B.
    Xu, K.
    Si, M.
    Li, H.
    Mao, R.
    Li, L.
    Kang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S49 - S50
12345